我們已在上線！進一步了解

Cue Biopharma

CUE

市值 US$1.21億

16.71 USD

-1.96

10.5%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

16.50

-0.21

1.26%

1天

-10.5%

5天

-39.1%

1個月

-51.1%

3個月

-39.87%

6個月

-9.48%

今年迄今

65.12%

1年

-29.49%

5年

-95.45%

10年

-95.21%

關於： Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

員工： 29

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 33.3%

中性 66.7%

負面 0%

Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response

Cue Biopharma NASDAQ: CUE reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines.

Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

I am initiating Cue Biopharma with a "Buy" rating, driven by positive phase 2 results for CUE-221 in chronic spontaneous urticaria [CSU]. CUE-221's novel dual mechanism of action demonstrated superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution at 12 weeks [p < 0.005]. Upcoming catalysts include 36-week PK and IgE data in 2026, and planned phase 2b/3 global studies in CSU and food allergy, targeting large market opportunities.

Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript

What's Going on With Cue Biopharma Stock on Monday?

Cue Biopharma (NASDAQ:CUE) on Sunday shared topline results from a Phase 2 trial of CUE-221 in patients with moderate to severe chronic spontaneous urticaria.

What's Going on With Cue Biopharma Stock on Monday?

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cue Biopharma, Inc. (NASDAQ: CUE) on behalf of the company's shareholders. The investigation seeks to determine whether Cue Biopharma's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer.

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

查看新聞排名

價格圖表採用Lightweight Charts™實作